Jonathan Chick, Castle Craig Hospital, Scotland
One of the central objectives of a diagnostic system is to provide precision of diagnosis for selecting available treatments. Correspondingly precision in diagnosis is essential for devising clinical trials, whether these be medications or behavioural therapies. The increasing comorbidity of other substances with alcohol use and of mental health disorders such as depression and trauma-related conditions add to the need for precision of diagnosis when potential treatments are being tested. This presentation will examine current practice in diagnostic assessment in clinical trials on alcohol use disorders, and will explore how the different diagnostic entities in the draft ICD 11 might aid diagnostic precision and case selection in clinical trials.
Illustrations will be given of trial outcomes showing that point.
However, dimensions within the syndrome will also merit assessment; to illustrate: within a sample of patients meeting criteria for Alcohol Use Disorder, a GABA – agonist might have more effect in the recovery of a patient whose syndrome dictated the need for a medicated withdrawal, than in a patient whose symptomatology did not show that constellation.